The majority of the HER2-positive BC patients were non-Hispanic White (subsequently referred to as White) (73.1%), with HR-positive disease (70.6%), no comorbidity (85.1%), residing in metropolitan areas (82%) and were treated with combination chemotherapy (79.5%). The gene discussed is ERBB2; the disease is breast cancer.